|
BL-B01D1 Clinical Trials
26 actively recruiting trials across 1 location
No change since May 2026
Also known as: BMS-986507, iza-bren, izalontamab brengitecan
Pipeline
Phase 1: 4Phase 2: 18Phase 3: 3Phase 1/2: 1
Top Sponsors
- Sichuan Baili Pharmaceutical Co., Ltd.24
- SystImmune Inc.1
- Sichuan University1
Indications
- Cancer26
- Lung Cancer9
- Non Small Cell Lung Cancer6
- Solid Tumor5
- Breast Cancer4
Other25 trials
Phase 2
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Phase 2
Phase 2
Phase 2
Beverly Hills, California1 trial
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Beverly Hills Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.